Cordis plans to acquire MedAlliance, the developer of the Selution SLR drug-eluting vascular balloon, for up to $1.135bn. As part of the deal, Cordis will immediately begin to co-promote Selution SLR in every market where it is available.
Cordis will pay $235m upfront and up to $900m in additional milestone payments to acquire MedAlliance, the privately held Swiss developer of the Selution SLR sirolimus-eluting vascular balloon.
Under the terms of the agreement announced on 18 October, Cordis will invest $35m in MedAlliance and begin co-promoting Selution SLR immediately. The companies expect the deal to close in...
The brunt of the tariff exposure stems from Singapore and Costa Rica, which together account for an estimated 70% to 80% of the tariff-related cost burden. Less than 10% of the exposure is tied to China.
A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.
The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.
